Skip to main content
SpringerLink
Log in

The Effect of Verapamil on Response of Coronary Vasomotion to Handgrip Exercise in Symptomatic Patients with Hypertrophic Cardiomyopathy

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Objectives. To assess the effect of verapamil on the response of diastolic coronary blood flow velocity (CBFV) and coronary vascular resistance index to handgrip exercise in symptomatic HCM patients.

Design. In 13 patients with HCM, the CBFV was detected in the distal portion of left anterior descending coronary artery using high-sensitivity transthoracic Doppler echocardiography. The peak diastolic CBFV and coronary vascular resistance index (calculated as the ratio of mean aortic pressure to CBFV) was measured at baseline and during handgrip exercise. Changes of these parameters induced by the exercise (expressed as the percentage of baseline values) were compared on verapamil treatment and after verapamil withdrawal. The same measurements were obtained in 10 healthy control subject.

Results. In HCM patients, the increase in CBFV during exercise was significantly higher on than off verapamil therapy (16.2 ± 5% versus 6.8 ± 3.8%, p < 0.001). In healthy controls, exercise-induced increase in CBFV was comparable to CBFV changes in HCM patients receiving verapamil (17.4 ± 5.7 versus 16.2 ± 5%, p < 0.05) and was significantly greater than the CBFV response in HCM patients off verapamil (17.4 ± 5.7% versus 6.8 ± 3.8 % p < 0.005). During exercise the coronary vascular resistance index decreased on verapamil and increased after drug withdrawal (−5.8 ± 5.6% versus 1.1 ± 5.1%, p < 0.001). In healthy controls the coronary vascular resistance index decreased during exercise −8.5 ± 4.5% to similar extent as in HCM patients on verapamil.

Conclusion. In HCM symptomatic patients, verapamil improved coronary vasomotor response to physical stress. Verapamil was able to restore adequate vasodilator response to handgrip exercise.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maron BJ, Wolfson JK, Epstein SE. Intramural (“small vessel”) coronary disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 8: 545-547.

    PubMed  Google Scholar 

  2. Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation 1987; 75: 1130-1139.

    PubMed  Google Scholar 

  3. Schwartzkopff B, Mundhenke M, Strauer BE. Alterations of architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: A possible cause for myocardial ischemia. J Am Coll Cardiol 1998; 31: 1089-1096.

    PubMed  Google Scholar 

  4. Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998; 97: 230-233.

    PubMed  Google Scholar 

  5. Kodama K, Hamada M, Kazatani Y, et al. Clinical characteristics in Japanese patients with coexistent hypertrophic cardiomyopathy and coronary vasospasm. Angiology 1998; 49: 849-855.

    PubMed  Google Scholar 

  6. Kodama K, Shigematsu Y, Hamada M, et al. The effect of coronary vasospasm on the direction of ST-segment deviation in patients with both hypertrophic cardiomyopathy and vasospastic angina. Chest 2000; 117: 1300-1308.

    PubMed  Google Scholar 

  7. Dimitrow PP, Krzanowski M, Niżankowski R, Szczeklik A, Dubiel JS. Verapamil improves of coronary vasomotion to cold pressor test in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy. Cardiovasc Drug Ther 1999; 13, 259-264.

    Google Scholar 

  8. Dimitrow PP, Krzanowski M, Niżankowski R, Szczeklik A, Dubiel JS. Comparison of the effect of verapamil and propranolol on response of coronary vasomotion to cold pressor test in symptomatic patients with hypertrophic cardiomyopathy. Cardiovasc Drug Ther 2000; 14: 643-650.

    Google Scholar 

  9. Iida H, Fujii T, Miura T, Yoshitake S, Kawamura A, Fujii A. Assessment of endothelium dependent coronary vasodilatation in hypertrophic cardiomyopathy. Circulation 1996; 94: I-502.

    Google Scholar 

  10. Choudhury L, Elliott P, Rimoldi O, et al. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Basic Res Cardiol 1999; 94: 49-59.

    PubMed  Google Scholar 

  11. Rosing DR, Condit JR, Maron BJ, et al. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III effects of long-term administration. Circulation 1981; 48: 545-553.

    Google Scholar 

  12. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: A new approach to the pharamcologic treatment of hypertrophic cardiomyopathy: II effects on exercise and symptomatic status. Circulation 1979; 60: 1208-1213.

    PubMed  Google Scholar 

  13. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Short-and long-term effects. Circulation 1985; 72: 853-864.

    PubMed  Google Scholar 

  14. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22: 796-804.

    PubMed  Google Scholar 

  15. Udelson JE, Bonow RO, O'Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989; 79: 1052-1060.

    PubMed  Google Scholar 

  16. Kaufmann Ph, Frielingsdorf J, Mandinov L, Seiler Ch, Hug R, Hess OM. Reversal of abnormal coronary vasomotion by calcium antagonists in patients with hypercholesterolemia. Circulation 1998; 97: 1348-1354.

    PubMed  Google Scholar 

  17. Frielingsdorf J, Kaufmann Ph, Seiler Ch, Vassalli G, Suter T, Hess OM. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996; 93: 1380-1387.

    PubMed  Google Scholar 

  18. Nienaber CA, Gambhir SS, Mody FV, et al. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. Circulation 1993; 87: 1580-1590.

    PubMed  Google Scholar 

  19. Report of World Health Organization /International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-842.

    Google Scholar 

  20. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: A discussion of nomenclature. Am J Cardiol 1979; 43: 1242-1244.

    PubMed  Google Scholar 

  21. Gilligan DM, Panza JA, Kilcoyne CM, Waclawiw MA, Casino PR, Quyyumi AA. Contribution of endothelium-derived nitric oxide to exercise-induced vasodilatation. Circulation 1994; 90: 2853-2858.

    PubMed  Google Scholar 

  22. Katz SD, Krum H, Khan T, Knecht M. Exercise-induced vasodilatation in forearm circulation of normal subjects and patients with congestive herat failure: Role of endotheliumderived nitric oxide. J Am Coll Cardiol 1996; 28: 585-590.

    PubMed  Google Scholar 

  23. Dyke ChK, Proctor DN, Dietz NM, Joyner MJ. Role of nitric oxide exercise hyperaemia during prolonged rhythmic handgrip in humans. J Physiol 1995; 488; 259-265.

    PubMed  Google Scholar 

  24. Berstein RD, Ochoa FY, Xu X, et al. Function and production of nitric oxide in the coronary circulation of the conscious dog during exercise. Circulation Research 1996; 79: 840-848.

    PubMed  Google Scholar 

  25. O'Leary DS, Dunlap RC, Glover KW. Role of endotheliumderived relaxing factor in hindlimb reactive and active hyperemia in conscious dogs. Am J Physiol 1994; 266: R1213-1219.

    PubMed  Google Scholar 

  26. Crowley JJ, Dardas PS, Harcombe AA, Shapiro LM. Transthoracic Doppler echocardiographic analysis of phasic coronary blood flow velocity in hypertrophic cardiomyopathy. Heart 1997; 77: 558-563.

    PubMed  Google Scholar 

  27. Hozumi T, Yoshida K, Akasaka T, et al. Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography. Comparison with invasive technique. J Am Coll Cardiol 1998; 32: 1251-1259.

    PubMed  Google Scholar 

  28. Caiati C, Montaldo C, Zedda N, Bina A, Iliceto S. New noninvasive method for coronary flow reserve assessment: Contrast-enhanced transthoracic second harmonic echo Doppler. Circulation 1999; 99: 771-778.

    PubMed  Google Scholar 

  29. Ishihara M, Sato H, Tateishi H, et al. Effects of various doses of intracoronary verapamil on coronary resistance vessels in humans. Jpn Circ J 1997; 61: 755-761.

    PubMed  Google Scholar 

  30. Antony G, Nitenberg A, Foult J-M, Aptecar E. Coronary vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy. J Am Coll Cardiol 1993; 22: 514-520.

    PubMed  Google Scholar 

  31. Sambuceti G, Marilli M, Marraccini P, et al. Coronary vasoconstriction during myocardial ischemia by rises in metabolic demand in patients with coronary artery disease. Circulation 1997; 95: 2652-2659.

    PubMed  Google Scholar 

  32. Rossen JD, Nahser PJ, Oskarsson H, et al. Does pharmacologic coronary flow reserve reflect vasodilator responsiveness to increased myocardial demand in humans? Cor Art Dis 1996; 7: 479-484.

    Google Scholar 

  33. Kyriakidis MK, Dernellis JM, Androulakis AE, et al. Changes in phasic coronary blood flow velocity profile and relative cornary flow reserve in patients with hypertrophic obstructive cardiomyopathy. Circulation 1997; 96: 834-841.

    PubMed  Google Scholar 

  34. Cannon RO 3rd, Rosing DR, Maron BJ, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: Contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985; 71: 234-243.

    PubMed  Google Scholar 

  35. Dimitrow PP, Krzanowski M, Niżankowski R, Szczeklik A, Dubiel JS. Effect of verapamil on systolic and diastolic coronary blood flow velocity in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy. Heart 2000; 83: 262-266.

    PubMed  Google Scholar 

  36. Watanabe T, Akutsu Y, Yamanaka H, et al. Exerciseinduced ST-segment depression: Imbalance between myocardial oxygen demand and myocardial blood flow. Acta Cardiol 2000; 55: 25-31.

    PubMed  Google Scholar 

  37. Kitamura K, Jorgensen Ch, Gobel FL, Taylor HL, Wang Y. Hemodynamic correlates of myocardial oxygen consumption during upright exercise. J Appl Physiol 1972; 32: 516-522.

    PubMed  Google Scholar 

  38. Krivokapich J, Smith GT, Huang SC, et al. 13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Circulation 1989; 80: 1328-1337.

    PubMed  Google Scholar 

  39. Globits S, Sakuma H, Shimakawa A, Foo TKF, Higgins CB. Measurement of coronary blood flow velocity during handgrip exercise using breath-hold velocity encoded cine magnetic resonance imaging. Am J Cardiol 1997; 79: 234-237.

    PubMed  Google Scholar 

  40. Kodama Y, Yokota M, Miyahara T, et al. Effect of antianginal agents on the relationship between rate-pressure product and myocardial oxygen uptake. Am Heart J 1993; 126: 587-593.

    PubMed  Google Scholar 

  41. Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol 1994; 74: 363-368.

    PubMed  Google Scholar 

  42. Takase H, Moreau P, Kung Ch, Nava E, Luscher TF. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency, effect of verapamil and trandolapril. Hypertension 1996; 27: 25-31.

    PubMed  Google Scholar 

  43. Dagenais F, Cartier R, Hollmann C, Buluran J. Calciumchannel blockers preserve endothelial reactivity after ischemia-reperfusion. Annals Thoracic Surgery 1997; 63: 1050-1056.

    Google Scholar 

  44. Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G. Effects of quinide and verapamil on human cardiovascular alpha 1-adrenoceptors. Circulation 1998; 97: 1227-1230.

    PubMed  Google Scholar 

  45. Bronztti E, Felici L, Polidori C, Amenta F. Interactions between calcium channel blockers and alpha-adrenoceptors in the human coronary and mammary arteries: A radioligand binding study. J Auton Pharmacol 1994; 14: 79-85.

    PubMed  Google Scholar 

  46. Vita JA, Treasure ChB, Yeung AC, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992; 85: 1390-1397.

    PubMed  Google Scholar 

  47. Baumgart D, Haude M, Gorge G, et al. Augmented α-adrenergic constriction of atherosclerotic human coronary arteries. Circulation 1999; 99: 2090-2097.

    PubMed  Google Scholar 

  48. Bassenge E, Stewart DJ. Interdependence of pharmacologically-induced and endothelium-mediated coronary vasodilatation in antianginal therapy. Cardiovasc Drugs Ther 1988; 1: 47-55.

    Google Scholar 

  49. Dohi Y, Criscione L, Pfeiffer K, Luscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: Studies in perfused mesenteric resistance arteries. J Cardiovasc Pharmacol 1994; 24: 372-379.

    PubMed  Google Scholar 

  50. Ritz MA, Luscher TF. Different potencies of endotheliumderived relaxing factors against thromboxane and endothelin-1 in coronary arteries: Comparison with nitrovasodilator and calcium antagonists. Coron Artery Dis 1991; 2: 1001-1008.

    Google Scholar 

  51. Haug C, Voisard R, Baur R, Hannekum A, Hombach V, Gruenert A. Effect of diltiazem and verapamil on endothelin release by cultured human coronary smooth-muscle cells and endothelial cells. J Cardiovasc Pharmacol 1998, 31(Suppl 1): S388-S391.

    PubMed  Google Scholar 

  52. Wilson RF, Laughlin DE, Ackell PH, et al. Transluminal subselective measurement of coronary artery flow velocity and vasodilator reserve in man. Circulation 1985; 72: 82-92.

    PubMed  Google Scholar 

  53. Reis SE, Holubkov R, Lee JS. Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of theWomen's ischemia syndrome evaluation (WISE) study. J Am Coll Cardiol 1999; 33: 1469-1475.

    PubMed  Google Scholar 

  54. Meeder JG, Peels HO, Blanksma PK, et al. Comparison between positron emission tomography myocardial perfusion imaging and intracoronary Doppler flow velocity measurements at and during cold pressor testing in angiographically normal coronary arteries in patients with onevessel coronary artery disease. Am J Cardiol 1996; 78: 526-531.

    PubMed  Google Scholar 

  55. Radvan J, Marwick TH, Williams J, Camici PG. Evaluation of the extent and timing of the coronary hyperemic resoponse to dipyridamole: A study with transesophageal echocardiography and positron emission tomography with oxygen 15 water. J Am Soc Echocardogr 1995; 8: 864-873.

    Google Scholar 

  56. Saraste M, Koskenvou JW, Knuuti J, et al. Coronary flow reserve: Measurement with transthoracic doppler echocardiography is reproducible and comparable with positron emission tomography. Clin Physiol 2001; 21: 114-122.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd Department of Cardiology, Jagiellonian University School of Medicine, Krakow, Poland

    Paweł Petkow Dimitrow & Jacek S. Dubiel

  2. Department of Internal Medicine, Jagiellonian University School of Medicine, Krakow, Poland

    Marek Krzanowski, Rafał Niżankowski & Andrzej Szczeklik

Authors
  1. Paweł Petkow Dimitrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marek Krzanowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rafał Niżankowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrzej Szczeklik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacek S. Dubiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dimitrow, P.P., Krzanowski, M., Niżankowski, R. et al. The Effect of Verapamil on Response of Coronary Vasomotion to Handgrip Exercise in Symptomatic Patients with Hypertrophic Cardiomyopathy. Cardiovasc Drugs Ther 15, 331–337 (2001). https://doi.org/10.1023/A:1012710731874

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012710731874

Search

Navigation